Neurogene (NASDAQ:NGNE - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at BMO Capital Markets in a note issued to investors on Thursday, MarketBeat.com reports. They presently have a $26.00 target price on the stock, up from their previous target price of $22.00. BMO Capital Markets' price objective would suggest a potential upside of 34.40% from the company's previous close.
Other equities analysts also recently issued research reports about the stock. Baird R W downgraded shares of Neurogene from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. Robert W. Baird downgraded shares of Neurogene from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $38.00 to $24.00 in a research note on Friday, May 16th. HC Wainwright cut their price target on shares of Neurogene from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, William Blair reaffirmed an "outperform" rating on shares of Neurogene in a research note on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $45.40.
View Our Latest Stock Report on Neurogene
Neurogene Stock Performance
NASDAQ NGNE traded down $0.42 during mid-day trading on Thursday, reaching $19.35. 31,968 shares of the stock were exchanged, compared to its average volume of 249,702. Neurogene has a 1-year low of $6.88 and a 1-year high of $74.49. The business's fifty day simple moving average is $15.84 and its 200 day simple moving average is $17.47. The stock has a market capitalization of $275.90 million, a PE ratio of -4.49 and a beta of 1.57.
Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.03). On average, analysts anticipate that Neurogene will post -4.27 EPS for the current year.
Insider Activity
In other Neurogene news, insider Stuart Cobb sold 6,797 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.15, for a total transaction of $102,974.55. Following the sale, the insider now directly owns 20,794 shares of the company's stock, valued at $315,029.10. The trade was a 24.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.64% of the company's stock.
Hedge Funds Weigh In On Neurogene
A number of hedge funds have recently modified their holdings of NGNE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Neurogene during the first quarter valued at about $327,000. Baker BROS. Advisors LP boosted its holdings in Neurogene by 120.4% during the first quarter. Baker BROS. Advisors LP now owns 1,486,200 shares of the company's stock valued at $17,403,000 after acquiring an additional 811,750 shares during the period. Corebridge Financial Inc. boosted its holdings in Neurogene by 13.8% during the first quarter. Corebridge Financial Inc. now owns 5,826 shares of the company's stock valued at $68,000 after acquiring an additional 705 shares during the period. Finally, Walleye Capital LLC lifted its stake in shares of Neurogene by 25.7% in the first quarter. Walleye Capital LLC now owns 94,083 shares of the company's stock valued at $1,102,000 after buying an additional 19,247 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Further Reading

Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.